Search results
Whose health matters? The diversity deficit in clinical trials - EconoTimes
EconoTimes· 5 hours agoThe gold standard for clinical trials — randomized controlled studies — often require thousands of...
NIH launches 2 clinical trials testing HIV drug on women, other minority groups
United Press International via Yahoo News· 12 hours agoThe National Institute of Health says they are seeking to now include underrepresented population...
Common heart problem ‘carries higher stroke and dementia risk than expected’
Press Association News via AOL· 16 minutes ago“With its prevalence continuing to rise, it is crucial that we develop strategies to prevent not...
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of...
Morningstar· 22 hours ago(NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions ...
Breaking News, Business, Financial and Economic News, World News from EconoTimes
EconoTimes· 5 hours agoEconoTimes is a fast growing non-partisan source of news and intelligence on global economy and...
ConcertAI to Advance Translational and Clinical Development Solutions in Collaboration with NVIDIA
KOIN News 6 Portland· 3 days agoConcertAI, the leading oncology real-world evidence data and AI SaaS technology company, today...
Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial
Clinical Trials Arena via Yahoo Finance· 6 days agoRecently, Medidata expanded its partnership with contract research organisation Worldwide Clinical...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 hours agoAt the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks
BMS stakes $80m on Prothena’s neurodegenerative candidate
Pharmaceutical Technology via Yahoo Finance· 7 days agoBMS’ Neuroscience Thematic Research Center...the US licence for Prothena’s PRX-005 for $80m in June...
Craig-Hallum bullish on Rezolute stock with new Buy rating By Investing.com
Investing.com· 19 hours agoDespite the clinical hold, Craig-Hallum views the shares of Rezolute as undervalued, considering the...